X @Bloomberg
Bloomberg·2026-03-05 06:22
Merck KGaA forecast a sluggish year ahead, with the possibility of falling profits, as generic competition for its multiple sclerosis drug Mavenclad weighs on its health care division https://t.co/aoE08bT2ZG ...